Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Outlook Therapeutics reported Q2 FY26 results with a GAAP net loss of $4.5 million, a significant improvement from $46.4 million year-over-year, largely due to $9.3 million in non-cash gains from warrant and note fair value changes. Core operational performance weakened, with adjusted net loss widening to $14.1 million from $12.4 million, while net revenue was negative $1.1 million due to fixed distribution costs exceeding sales. The company holds only $7.7 million in cash as of March 31, despite raising $8.2 million in net proceeds through two dilutive offerings in March and April 2026.
Key figures
- Guidance
- FDA decision expected in May 2026; Switzerland launch targeted for 2027
- Revenue Yoy
- N/A
- Rd expense
- 4500000
- Sga expense
- 9505000
- Weighted avg shares
- 81835900
- Cash and equivalents
- 7748000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.